Monitor for submission of compliance plan by May 26, 2026; potential reverse split or capital raise could dilute shareholders. Delisting would severely impact liquidity and institutional ownership.
TCRT drugs
TCRT drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 16 $2.83entry
- T+1 · 7mo ago +3.18%α +1.97% · $2.92
- T+5 · 7mo ago −2.47%α −3.46% · $2.76
- T+20 · 6mo ago −10.95%α −16.77% · $2.52
- T+60 · 4mo ago −26.36%α −33.41% · $2.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alaunos Therapeutics (TCRT) received a delisting notice from Nasdaq due to failing to maintain the $2.5 million minimum stockholders' equity requirement, reporting $2.15 million as of December 31, 2025. The company has 45 days to submit a compliance plan and may request a hearing if needed.
Key Facts
- Received Nasdaq delisting notice on April 9, 2026, for failing to meet $2.5 million stockholders' equity requirement
- Reported stockholders' equity of $2,153,000 as of December 31, 2025
- Does not meet alternative listing standards (market value or net income)
- Has 45 days (until May 26, 2026) to submit a compliance plan
- May request a hearing to appeal if plan is rejected
Financial Impact
Stockholders' equity of $2,153,000 vs. required $2,500,000
Risk Factors
- Failure to regain compliance could lead to delisting from Nasdaq
- Reduced investor confidence and liquidity if delisted
- Potential need for dilutive financing to meet equity requirements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-157126 |
| Document: 0001193125-26-157126-index-headers.html | 0001193125-26-157126 |
| Document: 0001193125-26-157126-index.html | 0001193125-26-157126 |
| Document: 0001193125-26-157126.txt | 0001193125-26-157126 |
Track record
14 reports on TCRT
1 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +23.27% at T+60 after the May 26, 2026 report. 3 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago S-3 Bearish 6/10 Entry $1.63 Now $1.60 +1.84% settles Dec 14
- Oct 23, 202624d ago 8-K Bullish 5/10 Entry $2.13 Now $1.60 −24.88% settles Nov 23
- Oct 21, 202626d ago 8-K Bullish 7/10 Entry $3.04 Now $1.60 −47.37% settles Nov 19
- Oct 15, 20264w ago SC 13D/A Neutral 6/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
- Oct 15, 20264w ago SC 13D Neutral 5/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
- Oct 13, 20264w ago Press Release Bullish 8/10 Entry $3.03 to $1.67 Now $1.60 −47.19% ▼ −44.88% −41.21% vs SPY
- Oct 13, 20264w ago 8-K Bullish 8/10 Entry $3.03 to $1.71 Now $1.60 −47.19% ▼ −43.56% −39.95% vs SPY
- Oct 9, 20265w ago 8-K Bearish 7/10 Entry $1.05 to $1.67 Now $1.60 −52.38% ▼ −59.05% −62.31% vs SPY
- Sep 18, 20268w ago Press Release Bearish 5/10 Entry $1.20 to $2.63 Now $1.60 −33.33% ▼ −119.17% −118.96% vs SPY
- Sep 16, 20268w ago 8-K Neutral 2/10 Entry $1.60 to $2.18 Now $1.60 +0.00% ▲ +36.25% +34.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers